Novo Nordisk Aktie
42,10
EUR
+0,35
EUR
+0,83
%
42,20
EUR
+0,38
EUR
+0,90
%
Novo Nordisk jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Novo Nordisk Aktie Analyse
| 03.07.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 29.06.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 28.06.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 27.06.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 26.06.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 23.05.23 | Novo Nordisk Overweight | Barclays Capital | |
| 23.05.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 22.05.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 05.05.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 05.05.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 05.05.23 | Novo Nordisk Outperform | Credit Suisse Group | |
| 27.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 20.04.23 | Novo Nordisk Overweight | Barclays Capital | |
| 18.04.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 14.04.23 | Novo Nordisk Overweight | Barclays Capital | |
| 13.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 13.04.23 | Novo Nordisk Outperform | Credit Suisse Group | |
| 12.04.23 | Novo Nordisk Overweight | Barclays Capital | |
| 11.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 24.03.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 23.03.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 22.03.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 14.03.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 09.03.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 13.02.23 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.02.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 02.02.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 01.02.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 25.01.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 25.01.23 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 25.01.23 | Novo Nordisk Overweight | Barclays Capital | |
| 16.01.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 09.01.23 | Novo Nordisk Overweight | Barclays Capital | |
| 03.01.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 23.12.22 | Novo Nordisk Overweight | Barclays Capital | |
| 07.12.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 14.11.22 | Novo Nordisk Overweight | Barclays Capital | |
| 08.11.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.11.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 03.11.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.11.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 02.11.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.11.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 24.10.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 14.10.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 14.10.22 | Novo Nordisk Overweight | Barclays Capital | |
| 07.10.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.10.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.10.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
Werbung
Werbung